MAP2K7 and cutaneous melanoma: The presence of BRAF mutations might be important in the future because BRAF/MEK inhibitors could possibly play a role in treatment of metastatic disease, as they is used in cutaneous melanoma where BRAF mutations at the same residue are present [120].